اسأل أو ابحث عن أي شيء...
Hot Research Today
Papers from every journal, all in one place. أنشئ موجزات مخصصة.
1w ago
Expert CommentaryCirculation Highlight
Level 1: Clinical Guideline
Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association
Implication
Tailored plans needed to improve GDMT access in older HF patients; extends recommendations to address age-specific barriers.
Circulation
1w agoOpen Access
Expert CommentaryACC Journal Scan Highlight
Level 2: RCT
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy
Aficamten monotherapy improves submaximal exercise VE/VCO2 slope by ~2.8 points vs metoprolol in symptomatic oHCM.
Implication
Aficamten may be preferred over metoprolol for exercise capacity in symptomatic obstructive HCM; extends RCT evidence for myosin inhibitors versus beta-blockade.
““These findings provide compelling justification for aficamten treatment as an appropriate alternative to current first-line treatment with metoprolol, to treat exercise intolerance in oHCM.””
— ACC Journal ScanView source
JAMA Cardiology
Harvard University
3w agoOpen Access
Featured in PodcastExpert CommentaryACC Journal Scan Highlight
Level 2: RCT
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis
TAVR with SAPIEN XT increases 10-year all-cause mortality ~13% versus surgery.
Implication
May favor surgery over early-generation TAVR for 10-year survival in intermediate-risk patients; challenges assumptions of long-term equivalence.
“Taken together, the studies show a likely early advantage of TAVR with respect to the important primary clinical endpoints, with a later catch-up of surgery, such that there are no major differences between the therapies at 5 years.”
— Dr. Tamim NazifView source
Journal of the American College of Cardiology
Stanford University
3w ago
Expert CommentaryCirculation Highlight
Level 1: Clinical Guideline
Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association
Implication
Prescribe physical activity for cardiometabolic gains irrespective of weight loss; extends evidence for multimodal obesity management.
Circulation
2w ago
Expert CommentaryFeatured in PodcastCirculation Highlight
Level 1: Clinical Guideline
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology
Implication
Scientific statement examines risk assessment for improving cardiovascular disease prevention strategies.
Circulation
3d agoOpen Access
Circulation Highlight
Level 1: Clinical Guideline
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
Implication
May inform perinatal HF care via expert consensus; leaves open standardized definitions and screening tools.
Circulation
1w ago
Circulation Highlight
Level 1: Clinical Guideline
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
Implication
May enhance CV endpoint consistency in oncology trials; leaves open effects on outcomes or regulatory decisions pending validation.
Circulation
3w agoOpen Access
Featured in PodcastExpert CommentaryACC Journal Scan Highlight
Level 3: Cohort Study
10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients
TAVR shows similar 10-year all-cause mortality to surgery in intermediate-risk patients.
Implication
Supports TAVR durability in intermediate-risk patients; extends PARTNER 2 follow-up yet leaves open need for randomized confirmation.
“Taken together, the studies show a likely early advantage of TAVR with respect to the important primary clinical endpoints, with a later catch-up of surgery, such that there are no major differences between the therapies at 5 years. However, we know that 6 to 10 years and beyond is really the test of time for these valves, and that’s where we’re starting to see some differences emerge.”
— Dr. Tamim NazifView source
Journal of the American College of Cardiology
Stanford University
3w ago
Trending on XExpert CommentaryACC Journal Scan Highlight
Level 3: Cohort Study
Resistance Training, Aerobic Activity, Television Viewing, and Risk of Major Cardiovascular Events in U.S. Women
Resistance training ≥2 hours weekly in women linked to ~20% lower major CVD risk.
Implication
Observational data should not yet change practice; extends evidence on resistance training for CVD prevention in women but requires trials.
“These findings suggest that, within an already active population, RT is associated with additional reductions in [cardiovascular disease] risk above and beyond overall aerobic activity. Alongside aerobic activity and reductions in sedentary behavior, RT may be an important component of public hea...”
— ACC Journal ScanView source
Journal of the American College of Cardiology
Harvard University
3w ago
Level 1: Meta-Analysis
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages
Finerenone reduces CV and kidney events and increases CKM syndrome regression ~66% versus placebo.
Implication
Supports finerenone across CKM stages in T2D-CKD; extends prior RCTs to include syndrome regression.
“Importantly, participants who experience new-onset AFib/AFL were at a substantially higher subsequent risk of adverse cardiovascular and kidney outcomes than were those who remained free of AFib/AFL during follow-up. These findings highlight the role of finerenone in reducing the risk of new-onset AFib/AFL, mitigating downstream complications, and ultimately improving outcomes in patients across the CKM spectrum.”
— Dr. Maria A. PabonView source
JAMA Cardiology
University of Michigan
